Results 251 to 260 of about 71,732 (355)

Matsupexole: A novel nonergot dopamine receptor agonist with sustained efficacy in a rat model of Parkinson's disease and limited off‐target activity

British Journal of Pharmacology, Volume 183, Issue 10, Page 2518-2532, May 2026.
Background and Purpose Dopamine receptor agonists, particularly targeting the dopamine D2L receptor (D2LR), have been used to treat Parkinson's disease (PD). However, valvular heart disease and somnolence, mainly caused by activating the serotonin 5‐HT2B receptor (5‐HT2BR) and dopamine D3 receptor (D3R), respectively, currently challenge their clinical
Takayuki Suzuki, Fumiki Oana, Masaki Oota, Yuma Handa, Osamu Kaminuma   +4 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study.

BMJ
Cai M, Choi T, Xie Y, Al-Aly Z.
europepmc   +1 more source

Cardiovascular adverse effects of common non-oncologic medications: from mechanisms to clinical management. [PDF]

Eur Heart J Cardiovasc Pharmacother
Bahit MC, Agudo-Quilez P, Zamorano J, Gibson CM.   +3 more
europepmc   +1 more source

Synthesis and Structure–Activity Relationships of 2,5-Dimethoxy-4-Substituted Phenethylamines and the Discovery of CYB210010: A Potent, Orally Bioavailable and Long-Acting Serotonin 5-HT₂ Receptor Agonist

Geoffrey B. Varty, Clinton E. Canal, Tina A. Mueller, Joshua A. Hartsel, Richa Tyagi, Ken Avery, Michael Morgan, Amy C. Reichelt, Pradip M. Pathare, Erik M. Stang, Michael G. Palfreyman, Alex Nivorozhkin   +11 more
openalex   +1 more source

Depletion of serotonin decreases the effects of the kappa-opioid receptor agonist U-69593 on cocaine-stimulated activity

, 2008
Елена Захарова, Stephanie L. Collins, Maria Åberg, Adarsh Kumar, Jesus B. Fernandez, Sari Izenwasser   +5 more
openalex   +2 more sources

Review: “The Disappointment Dilemma: Short‐ and Long‐Term Learning From Negative Outcomes”

European Journal of Neuroscience, Volume 63, Issue 9, May 2026.
The habenula routes negative‐outcome signals to VTA, RMTg, and IPN to shape aversive learning and motivation. The lateral habenula encodes acute negative prediction errors to rapidly adapt behavior to threat, fear, and avoidance. The medial habenula integrates repeated stress, drug, and aversive experiences into long‐term negative mood and expectations.
Ines Ibañez‐Tallon, Susanna Molas, Christophe D. Proulx, Joaquin Piriz, Edgar Soria‐Gómez   +4 more
wiley   +1 more source

Felcisetrag stimulates 5-HT₄-serotonin receptors in the human atrium. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Abella LMR, Neumann J, Hofmann B, Kirchhefer U, Gergs U.   +4 more
europepmc   +1 more source

Gαi1/3 Is a Novel Regulatory Target for RANKL Signal Transduction and Osteoporosis

Advanced Science, Volume 13, Issue 20, 9 April 2026.
ABSTRACT Osteoporosis, characterized by progressive bone loss and increased fracture risk, is a growing concern as the population ages. Current treatments, though advanced, remain limited, underscoring the necessity for novel therapeutic targets. Recent studies have shown that the immune system plays a key role in osteoporosis, with osteoclasts driving
Chaowen Bai, Mingchao Zhang, Le Liu, Lide Tao, Chenyang Xu, Hao Chai, Xin Shi, Yin Wang, Xiaopei Zhang, Qiong Chen, Dong Liu, Jinyu Bai, Chang She, Xiaozhong Zhou, Cong Cao, Huajian Shan   +15 more
wiley   +1 more source

Medicines for Anxiety: A Hundred Years of Tranquillity and More to Come? [PDF]

Hum Psychopharmacol
Nutt D.
europepmc   +1 more source

Virus-induced serotonin production correlates with severity of inflammation-associated ocular disease: Therapeutic potential of 5HT2A receptor agonists

, 2020
Timothy P. Foster, Diana M. Battaglia, Maria Dulfary Sanchez‐Pino, Charles D. Nichols   +3 more
openalex   +1 more source